Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.

Kallenberg, Cees G. M.; Pastoor, G. W.; Wouda, A. A.; The, T. H.

doi:10.1136/ard.41.4.382

Cited by 101 publications

(28 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With regard to serologic markers they found ANA positivity in only 9% of ACA-positive patients but in 50% of the ACA-negative group [24]. Kallenberg and coworkers reported that 75% of patients with SSc who were seropositive for ACA had pulmonary disease involvement [25]. Fritzler et al and Mc Carty et al pointed out the decreased frequency of cardiac and renal involvement in ACA-positive patients [26,27].…”

Section: Discussionmentioning

confidence: 98%

Autoantibody Profile in Systemic Sclerosis as a Marker for Esophageal and Other Organ Involvement in Turkish Populations

et al. 2007

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a connective tissue disorder of unknown etiology characterized by fibrosis and vascular obliteration in the skin, gastrointestinal tract, lungs, and heart. Our aim was to investigate the autoantibody profile in patients with esophageal involvement of SSc and to describe the relationship between the autoantibody profile and organ involvement in SSc. We studied 47 SSc patients, all with esophageal involvement shown on esophageal manometry. The patients were separated into three groups based on the absence or presence of ANA, Scl70, and ACA. In this study ANA and Scl70 were present more frequently than ACA in patients with esophageal involvement of SSc. Pulmonary involvement and heart involvement were seen more in Scl70-positive and ACA-positive patients, respectively. We conclude that in patients with SSc, closer follow-up with autoantibody profile may enable early diagnosis of specific organ involvement and treatment of debilitating symptoms, with avoidance of potential life-threatening complications.

show abstract

Section: Discussionmentioning

confidence: 98%

Autoantibody Profile in Systemic Sclerosis as a Marker for Esophageal and Other Organ Involvement in Turkish Populations

et al. 2007

View full text Add to dashboard Cite

show abstract

“…However, wc and other investiga tors have discovered that this antibody can also be found in patients suffering from other diseases. The antibody has frequently been detected in cases of primary biliary cirrhosis [ 10. 111 and in cases of Raynaud's phenomenon alone [2,7,12]. Additionally, this antibody has been reported to be present occasionally in cases of systemic lupus erythematosus [2,7,13], localized scleroderma [14][15][16] and the blood relatives of patients with systemic scle rosis [5.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Study of Patients with Anticentromere Antibody

Takehara

Soma²,

Igarashi³

et al. 1990

Dermatology

View full text Add to dashboard Cite

As has previously been reported by many investigators the anticentromere antibody is considered to be a useful serologic marker for the CREST (calcinosis, Raynaud’s phenomenon, esophageal involvement, sclerodactyly and telangiectasia) variant of systemic sclerosis. However, this antibody also appears in other conditions. By screening antinuclear antibody tests using HEp-2 cells as substrate, 39 patients were shown to have the anticentromere antibody. These patients were divided into 4 groups: group 1 = 17 patients with systemic sclerosis; group 2 = 9 patients with Raynaud’s phenomenon alone; group 3 = 7 patients with other connective-tissue diseases, and group 4 = 6 patients with conditions other than those present in groups 1–3. Follow-up over years revealed that some patients suffering solely from Raynaud’s phenomenon (group 2) developed the symptoms of systemic sclerosis. In contrast, of the patients who did not have Raynaud’s phenomenon (group 4), none developed any symptom suggesting systemic sclerosis. We suggest that the simultaneous presence of Raynaud’s phenomenon and the anticentromere antibody predicts the occurrence of systemic sclerosis. In contrast, the presence of the anticentromere antibody alone cannot necessarily be used to predict the development of systemic sclerosis.

show abstract

“…Anti-centromere antibodies (ACA)' are present in sera of certain patients with scleroderma, particularly the calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia (CREST) variant (1)(2)(3)(4)(5). ACA also have been found infrequently in some individuals with rheumatoid arthritis (6), pulmonary fibrosis (7), and primary biliary cirrhosis associated with CREST (8,9).…”

Section: Introductionmentioning

confidence: 99%

Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies.

Earnshaw¹,

Bordwell²,

Marino³

et al. 1986

J. Clin. Invest.

202

113

View full text Add to dashboard Cite

show abstract

Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.

Cited by 101 publications

References 12 publications

Autoantibody Profile in Systemic Sclerosis as a Marker for Esophageal and Other Organ Involvement in Turkish Populations

Autoantibody Profile in Systemic Sclerosis as a Marker for Esophageal and Other Organ Involvement in Turkish Populations

Longitudinal Study of Patients with Anticentromere Antibody

Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies.

Contact Info

Product

Resources

About